Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Sold by Meitav Investment House Ltd.

Meitav Investment House Ltd. lowered its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 33.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,370,855 shares of the company’s stock after selling 695,467 shares during the period. Meitav Investment House Ltd.’s holdings in Cellebrite DI were worth $30,200,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. FMR LLC lifted its stake in shares of Cellebrite DI by 136.3% in the 3rd quarter. FMR LLC now owns 5,616,757 shares of the company’s stock valued at $94,586,000 after purchasing an additional 3,239,307 shares in the last quarter. Principal Financial Group Inc. bought a new position in Cellebrite DI during the 3rd quarter valued at $23,402,000. Lord Abbett & CO. LLC bought a new stake in Cellebrite DI in the third quarter valued at about $11,523,000. Summit Partners Public Asset Management LLC acquired a new stake in shares of Cellebrite DI during the 3rd quarter valued at approximately $9,274,000. Finally, Telemark Asset Management LLC acquired a new position in shares of Cellebrite DI in the 3rd quarter valued at about $6,736,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Stock Down 3.1 %

CLBT opened at $19.66 on Thursday. Cellebrite DI Ltd. has a 52 week low of $10.24 and a 52 week high of $26.30. The company has a fifty day moving average price of $22.57 and a two-hundred day moving average price of $19.33.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, research analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on CLBT. Lake Street Capital increased their price objective on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Craig Hallum increased their price objective on Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Needham & Company LLC restated a “buy” rating and issued a $28.00 price target on shares of Cellebrite DI in a research report on Friday, February 14th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $23.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.